Analysts Set BeiGene, Ltd. (BGNE) PT at $73.25

BeiGene, Ltd. (NASDAQ:BGNE) has received an average recommendation of “Buy” from the seven brokerages that are presently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $74.80.

Several equities analysts recently weighed in on the stock. Maxim Group set a $57.00 price target on shares of BeiGene and gave the stock a “buy” rating in a report on Saturday, July 1st. Zacks Investment Research upgraded BeiGene from a “sell” rating to a “buy” rating and set a $79.00 price objective on the stock in a research report on Tuesday, July 11th. Robert W. Baird upped their price objective on BeiGene from $44.00 to $58.00 and gave the stock an “outperform” rating in a research report on Thursday, July 6th. Ladenburg Thalmann Financial Services assumed coverage on BeiGene in a research report on Monday. They issued a “buy” rating and a $81.00 price objective on the stock. Finally, Morgan Stanley restated an “overweight” rating and issued a $83.00 price objective on shares of BeiGene in a research report on Monday, July 10th.

BeiGene (NASDAQ:BGNE) traded down 1.40% during mid-day trading on Friday, reaching $77.30. 100,165 shares of the company’s stock were exchanged. The company’s 50-day moving average is $59.96 and its 200 day moving average is $43.43. The firm’s market capitalization is $3.07 billion. BeiGene has a one year low of $26.05 and a one year high of $79.81.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Rincon Hill News and is the property of of Rincon Hill News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://rinconhillneighbors.org/2017/08/20/analysts-set-beigene-ltd-bgne-pt-at-73-25-updated.html.

In other BeiGene news, Director Xiaodong Wang sold 5,539 shares of the company’s stock in a transaction that occurred on Friday, June 2nd. The stock was sold at an average price of $40.00, for a total value of $221,560.00. Following the sale, the director now owns 55,000 shares in the company, valued at approximately $2,200,000. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO John Oyler sold 219,400 shares of the company’s stock in a transaction that occurred on Thursday, July 6th. The stock was sold at an average price of $64.82, for a total value of $14,221,508.00. Following the completion of the sale, the chief executive officer now owns 212,055 shares in the company, valued at approximately $13,745,405.10. The disclosure for this sale can be found here. In the last 90 days, insiders sold 389,249 shares of company stock worth $22,594,820.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP raised its position in shares of BeiGene by 15.8% in the first quarter. Wellington Management Group LLP now owns 1,256,825 shares of the company’s stock worth $46,013,000 after buying an additional 171,704 shares during the period. OppenheimerFunds Inc. acquired a new position in shares of BeiGene during the first quarter worth about $2,086,000. Emory University acquired a new position in shares of BeiGene during the first quarter worth about $2,111,000. Vident Investment Advisory LLC raised its position in shares of BeiGene by 19.2% in the first quarter. Vident Investment Advisory LLC now owns 29,746 shares of the company’s stock worth $1,089,000 after buying an additional 4,788 shares during the period. Finally, Ariose Capital Management Ltd raised its position in shares of BeiGene by 414.5% in the first quarter. Ariose Capital Management Ltd now owns 198,609 shares of the company’s stock worth $7,271,000 after buying an additional 160,010 shares during the period. Hedge funds and other institutional investors own 43.85% of the company’s stock.

BeiGene Company Profile

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Analyst Recommendations for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related companies with our FREE daily email newsletter.

 

Latest News



Leave a Reply

 
© 2006-2017 Rincon Hill News.